GSK Resubmits Tebipenem HBr NDA for Complicated UTIs After Phase 3 Non-Inferiority Data
GlaxoSmithKline resubmitted its NDA for tebipenem HBr to the FDA for complicated UTIs after positive Phase 3 non-inferiority trial results.
Read MoreALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
GlaxoSmithKline resubmitted its NDA for tebipenem HBr to the FDA for complicated UTIs after positive Phase 3 non-inferiority trial results.
Read MoreGilead Sciences submitted an NDA to the FDA for bulevirtide 10 mg to treat chronic hepatitis delta virus, supported by Phase 3 MYR301 data.
Read MoreThe FDA extended its review of Aldeyra’s reproxalap for dry eye disease to March 16, 2026, after requesting a clinical study report.
Read MoreThe FDA approved ICOTYDE (icotrokinra) for treating moderate-to-severe plaque psoriasis in patients 12 and older weighing at least 40 kg.
Read MoreSignificant strides in pediatric care emerge as the FDA clears ET-600 for arginine vasopressin deficiency—discover what this means for treatment safety and outcomes.
Read MoreAutism spectrum disorder (ASD) is a neurodevelopmental disorder that affects an individual’s social interactions and communication.1 In recent decades, the
Read MoreAn entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark
Read MoreMore than $4.3 billion in opioid settlement money has landed in the hands of city, county and state officials to
Read MoreRaw garlic is compared to roasted, stir-fried, simmered, and jarred garlic. Garlic lowers blood pressure, regulates cholesterol, and stimulates immunity.
Read MoreA wide-ranging lawsuit filed Friday outlines a moneymaking scheme by which large insurance sales agency call centers enrolled people into
Read More